Shingrix logo

Product menu

Smiling couple walking on sunny beach
Hear from the experts, on Shingles vaccination:

Introducing SHINGRIX▼ (herpes zoster vaccine, recombinant, adjuvanted)

Hear from the experts on the Impact Shingles can have 

90% of adults In the UK carry the virus that causes shingles1. Find out more about the impact this can have on patients.

  • Why does the risk of Shingles increase?

    Why does the risk of Shingles increase?

    Risks in ageing immune systems and compromised immune systems.

    Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.5,6

    Find out more

  • Clinical profile of Shingrix

    Clinical profile of Shingrix 

    Efficacy and Safety data in age 50+ Immunocompetent populations.

    SHINGRIX has a clinically acceptable safety and tolerability profile.1-4

    Find out more

  • Clinical profile of Shingrix in Immunocompromised patients

    Clinical profile of Shingrix in Immunocompromised patients

    Efficacy and Safety data in 18+ Immunocompromised populations.

    SHINGRIX has demonstrated efficacy in two immunocompromised (IC) patient populations ≥18 years of age (includes post-hoc analyses).1,2

    Find out more

  • Shingrix product Information

    Shingrix practical considerations and administration 

    Dosing schedule, administration, contraindications, storage, reconstitution and availability information.

    SHINGRIX is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in: adults 50 years of age or older; adults 18 years of age or older at increased risk of HZ.1,2

    Find out more

  • Where could different patient populations be vaccinated with Shingrix?

    Where could different patient populations be vaccinated with Shingrix?:

    Shingrix availability in the UK and considerations on where the most effective place to vaccinate different patient populations could be, including those within the Shingles National Programme, those 50+ and Immunocompromised patients.8

    Get the information you need to administer SHINGRIX to adults 50 years of age and older with confidence.1,2

    Find out more

Learn more about SHINGRIX

Efficacy Icon – 90%

How efficacious is SHINGRIX?

SHINGRIX demonstrated >90% efficacy against shingles in adults 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.4,5,7,8

review efficacy data

1 in 4 icon - 4 cartoon outlines

Who can benefit from SHINGRIX?

There is a 1 in 4 lifetime risk of developing shingles.3 Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.1,2

View Patient Profiles

Safety Icon – red cross

Learn more about the safety profile of SHINGRIX

The majority of local and systemic adverse reactions were mild to moderate and transient, based on two large, phase 3 randomised controlled trials. Reactions reported as severe lasted 1 to 2 days.4,5,7,8

Explore safety data

References

  1. Shingrix, GB Summary of Product Characteristics (SPC)
  2. Shingrix, NI Summary of Product Characteristics (SPC)
  3. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372(22):2087-96.
  4. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375(11):1019-32.
  5. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356 (13): 1338-43.
  6. Gauthier et al. Epidemiology and costs of herpes zoster and postherpetic neuralgia in the United Kingdom . Epidemiol infecti. 2009; 137: 38-472.
  7. DH Green Book ch 34 Varicella pg 422. August 2015
  8. DH Green Book ch 28a - Shingles. August 2021.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

September 2022 | PM-GB-SGX-WCNT-220010 (V1.0)